Alentis Therapeutics, a Basel, Switzerland-based clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors, raised US$105m in Series C financing.
The round was led by Jeito Capital with Novo Holdings A/S and RA Capital Management and participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio Fund 2, and Schroders Capital. Novo Holdings’ Naveed Siddiqi joined join Alentis’ Board of Directors.
The company intends to use the funds for the clinical development of its lead investigational products ALE.F02 and ALE.C04 as well as the CLDN1 platform development.
Led by Dr. Roberto Iacone, CEO, Alentis Therapeutics is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors with immune evasive properties and fibrotic disease across multiple organs.
Founded in 2019 based on research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm), the company is headquartered in Basel’s pharma-biotech hub in Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.
Alentis has made major steps in the last two years: the ALE.F02 MAD study completion is imminent. The team has clearly defined the CLDN1+ cancer patient population, including T-cell excluded cancers to develop ALE.C04 in oncology. They also established the platform to engineer CLDN1 antibody drug conjugates and bi-specific antibodies that the Series C will help to further develop. Alentis is expanding its team of top talent.
FinSMEs
13/04/2023